<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00300677</url>
  </required_header>
  <id_info>
    <org_study_id>A1501079</org_study_id>
    <nct_id>NCT00300677</nct_id>
  </id_info>
  <brief_title>To Determine The Amount Of Voriconazole In The Brain After 2 Loading Doses And 3 Maintenance Doses Over 3 Days</brief_title>
  <official_title>Assessment Of Voriconazole Penetration Into The Brain By Fluorine-Magnetic Resonance Spectroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McLean Hospital. Belmont, MA.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the amount of voriconazole in the brain after 2 loading doses and 3 maintenance
      doses over 3 days and compare it to the amount of voriconazole in the plasma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Concentrations of Voriconazole</measure>
    <time_frame>Day 3: pre-dose, 2 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain Concentrations of Voriconazole</measure>
    <time_frame>Day 3: pre-dose, 2 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentrations of N-oxide Metabolite</measure>
    <time_frame>Day 3: pre-dose, 2 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain Concentrations of N-oxide Metabolite</measure>
    <time_frame>Day 3: pre-dose, 2 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Infections, Fungal</condition>
  <arm_group>
    <arm_group_label>voriconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>voriconazole twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>voriconazole</intervention_name>
    <description>Multiple oral doses of voriconazole at 400 mg loading twice daily followed by 200 mg maintenance twice daily</description>
    <arm_group_label>voriconazole</arm_group_label>
    <other_name>Vfend</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be willing and able to provide informed consent.

          -  Subjects must be willing and able to be confined at the Clinical Research Unit as
             required by the protocol.

        Exclusion Criteria:

          -  Subjects with any condition affecting drug absorption.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478-1041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1501079&amp;StudyName=To%20Determine%20The%20Amount%20Of%20Voriconazole%20In%20The%20Brain%20After%202%20Loading%20Doses%20And%203%20Maintenance%20Doses%20Over%203%20Days%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2006</study_first_submitted>
  <study_first_submitted_qc>March 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2006</study_first_posted>
  <results_first_submitted>August 26, 2009</results_first_submitted>
  <results_first_submitted_qc>October 5, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 14, 2009</results_first_posted>
  <last_update_submitted>October 5, 2009</last_update_submitted>
  <last_update_submitted_qc>October 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer Inc</organization>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Voriconazole</keyword>
  <keyword>Magnetic Resonance Spectroscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voriconazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy male volunteers were recruited by 1 hospital center in the U.S. between March 2007 and August 2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Voriconazole</title>
          <description>400 mg every 12 hours on Day 1; 200 mg every 12 hours on Day 2; 200 mg on Day 3</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Voriconazole</title>
          <description>400 mg every 12 hours on Day 1; 200 mg every 12 hours on Day 2; 200 mg on Day 3</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18-25 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>26-35 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36-45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Concentrations of Voriconazole</title>
        <description>Mean plasma voriconazole concentrations (nanograms per milliliter [ng/mL]) pre-dose (Cmin) and two hours post-dose (C2h). Plasma samples were assayed using a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometry (HPLC-MS/MS) method.</description>
        <time_frame>Day 3: pre-dose, 2 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set: subjects included in the statistical analysis of pharmacokinetic parameters had the pharmacokinetic parameter of interest. N=number of observations (non-missing concentrations).</population>
        <group_list>
          <group group_id="O1">
            <title>Voriconazole</title>
            <description>400 mg every 12 hours on Day 1; 200 mg every 12 hours on Day 2; 200 mg on Day 3</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentrations of Voriconazole</title>
          <description>Mean plasma voriconazole concentrations (nanograms per milliliter [ng/mL]) pre-dose (Cmin) and two hours post-dose (C2h). Plasma samples were assayed using a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometry (HPLC-MS/MS) method.</description>
          <population>Pharmacokinetic Analysis Set: subjects included in the statistical analysis of pharmacokinetic parameters had the pharmacokinetic parameter of interest. N=number of observations (non-missing concentrations).</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>predose (Cmin)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="839.50" spread="874.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours postdose (C2h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2182.33" spread="1190.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Other estimated parameter represents the Day 3 pre-dose ratio of the adjusted geometric means comparing brain vs. plasma concentrations of voriconazole. Natural-log transformed concentrations of voriconazole were analyzed using a mixed-effects model to obtain the adjusted mean difference (Test-Reference) and 90% confidence interval for the difference which were exponentiated to provide estimates of the ratio of the adjusted geometric means and 90% CI for the ratio.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>predose: ratio adjusted geometric means</param_type>
            <param_value>300.28</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>192.91</ci_lower_limit>
            <ci_upper_limit>467.43</ci_upper_limit>
            <estimate_desc>Estimated value = ratio (%) of adjusted geometric means comparing brain (test) vs. plasma (reference) concentrations of voriconazole.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Other estimated parameter represents the Day 3 post-dose ratio of the adjusted geometric means comparing brain vs. plasma concentrations of voriconazole. Natural-log transformed concentrations of voriconazole were analyzed using a mixed-effects model to obtain the adjusted mean difference (Test-Reference) and 90% confidence interval for the difference which were exponentiated to provide estimates of the ratio of the adjusted geometric means and 90% CI for the ratio.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>postdose: ratio adjusted geometric means</param_type>
            <param_value>192.72</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>123.81</ci_lower_limit>
            <ci_upper_limit>300.00</ci_upper_limit>
            <estimate_desc>Estimated value = ratio (%) of adjusted geometric means comparing brain (test) vs. plasma (reference) concentrations of voriconazole.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Brain Concentrations of Voriconazole</title>
        <description>Mean brain concentrations (ng/mL) of voriconazole pre-dose and 2 hours post-dose measured by Fluorine (F) Magnetic Resonance Spectroscopy (F-MRS).</description>
        <time_frame>Day 3: pre-dose, 2 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set: subjects included in the statistical analysis of pharmacokinetic parameters had the pharmacokinetic parameter of interest. N=number of observations (non-missing concentrations).</population>
        <group_list>
          <group group_id="O1">
            <title>Voriconazole</title>
            <description>400 mg every 12 hours on Day 1; 200 mg every 12 hours on Day 2; 200 mg on Day 3</description>
          </group>
        </group_list>
        <measure>
          <title>Brain Concentrations of Voriconazole</title>
          <description>Mean brain concentrations (ng/mL) of voriconazole pre-dose and 2 hours post-dose measured by Fluorine (F) Magnetic Resonance Spectroscopy (F-MRS).</description>
          <population>Pharmacokinetic Analysis Set: subjects included in the statistical analysis of pharmacokinetic parameters had the pharmacokinetic parameter of interest. N=number of observations (non-missing concentrations).</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>predose (Cmin)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2090.44" spread="1227.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours postdose (C2h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4165.20" spread="1806.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Other estimated parameter represents the Day 3 pre-dose ratio of the adjusted geometric means comparing brain vs. plasma concentrations of voriconazole. Natural-log transformed concentrations of voriconazole were analyzed using a mixed-effects model to obtain the adjusted mean difference (Test-Reference) and 90% confidence interval for the difference which were exponentiated to provide estimates of the ratio of the adjusted geometric means and 90% CI for the ratio.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>predose: ratio adjusted geometric means</param_type>
            <param_value>300.28</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>192.91</ci_lower_limit>
            <ci_upper_limit>467.43</ci_upper_limit>
            <estimate_desc>Estimated value = ratio (%) of the adjusted geometric means comparing brain (test) vs. plasma (reference) concentrations of voriconazole.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Other estimated parameter represents the Day 3 post-dose ratio of the adjusted geometric means comparing brain vs. plasma concentrations of voriconazole. Natural-log transformed concentrations of voriconazole were analyzed using a mixed-effects model to obtain the adjusted mean difference (Test-Reference) and 90% confidence interval for the difference which were exponentiated to provide estimates of the ratio of the adjusted geometric means and 90% CI for the ratio.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>postdose: ratio adjusted geometric means</param_type>
            <param_value>192.72</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>123.81</ci_lower_limit>
            <ci_upper_limit>300.00</ci_upper_limit>
            <estimate_desc>Estimated value = ratio (%) of adjusted geometric means comparing brain (test) vs. plasma (reference) concentrations of voriconazole.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Concentrations of N-oxide Metabolite</title>
        <description>Mean plasma concentrations of voriconazole N-oxide metabolite (ng/mL) pre-dose and 2 hours post-dose. Plasma samples were assayed using a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometry (HPLC-MS/MS) method.</description>
        <time_frame>Day 3: pre-dose, 2 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set: subjects included in the statistical analysis of pharmacokinetic parameters had the pharmacokinetic parameter of interest. N=number of observations (non-missing concentrations).</population>
        <group_list>
          <group group_id="O1">
            <title>Voriconazole</title>
            <description>400 mg every 12 hours on Day 1; 200 mg every 12 hours on Day 2; 200 mg on Day 3</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentrations of N-oxide Metabolite</title>
          <description>Mean plasma concentrations of voriconazole N-oxide metabolite (ng/mL) pre-dose and 2 hours post-dose. Plasma samples were assayed using a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometry (HPLC-MS/MS) method.</description>
          <population>Pharmacokinetic Analysis Set: subjects included in the statistical analysis of pharmacokinetic parameters had the pharmacokinetic parameter of interest. N=number of observations (non-missing concentrations).</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>predose (Cmin)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3076.67" spread="841.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours postdose (C2h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3665.00" spread="958.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Other estimated parameter represents the Day 3 pre-dose ratio of the adjusted geometric means comparing brain vs. plasma concentrations of voriconazole N-oxide. Natural-log transformed concentrations of voriconazole were analyzed using a mixed-effects model to obtain the adjusted mean difference (Test-Reference) and 90% confidence interval for the difference which were exponentiated to provide estimates of the ratio of the adjusted geometric means and 90% CI for the ratio.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>predose: ratio adjusted geometric means</param_type>
            <param_value>12.39</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>7.09</ci_lower_limit>
            <ci_upper_limit>21.65</ci_upper_limit>
            <estimate_desc>Estimated value = ratio (%) of adjusted geometric means comparing brain (test) vs. plasma (reference) concentrations of voriconazole N-oxide.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Other estimated parameter represents the Day 3 post-dose ratio of the adjusted geometric means comparing brain vs. plasma concentrations of voriconazole N-oxide. Natural-log transformed concentrations of voriconazole were analyzed using a mixed-effects model to obtain the adjusted mean difference (Test-Reference) and 90% confidence interval for the difference which were exponentiated to provide estimates of the ratio of the adjusted geometric means and 90% CI for the ratio.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>postdose: ratio adjusted geometric means</param_type>
            <param_value>31.57</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>18.06</ci_lower_limit>
            <ci_upper_limit>55.18</ci_upper_limit>
            <estimate_desc>Estimated value = ratio (%) of adjusted geometric means comparing brain (test) vs. plasma (reference) concentrations of voriconazole N-oxide.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Brain Concentrations of N-oxide Metabolite</title>
        <description>Mean brain concentrations (ng/mL) of voriconazole N-oxide metabolite pre-dose and 2 hours post-dose measured by Fluorine (F) Magnetic Resonance Spectroscopy (F-MRS).</description>
        <time_frame>Day 3: pre-dose, 2 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set: subjects included in the statistical analysis of pharmacokinetic parameters had the pharmacokinetic parameter of interest. N=number of observations (non-missing concentrations).</population>
        <group_list>
          <group group_id="O1">
            <title>Voriconazole</title>
            <description>400 mg every 12 hours on Day 1; 200 mg every 12 hours on Day 2; 200 mg on Day 3</description>
          </group>
        </group_list>
        <measure>
          <title>Brain Concentrations of N-oxide Metabolite</title>
          <description>Mean brain concentrations (ng/mL) of voriconazole N-oxide metabolite pre-dose and 2 hours post-dose measured by Fluorine (F) Magnetic Resonance Spectroscopy (F-MRS).</description>
          <population>Pharmacokinetic Analysis Set: subjects included in the statistical analysis of pharmacokinetic parameters had the pharmacokinetic parameter of interest. N=number of observations (non-missing concentrations).</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>predose (Cmin)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="663.97" spread="677.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours postdose (C2h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1535.40" spread="1280.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Other estimated parameter represents the Day 3 pre-dose ratio of the adjusted geometric means comparing brain vs. plasma concentrations of voriconazole N-oxide. Natural-log transformed concentrations of voriconazole were analyzed using a mixed-effects model to obtain the adjusted mean difference (Test-Reference) and 90% confidence interval for the difference which were exponentiated to provide estimates of the ratio of the adjusted geometric means and 90% CI for the ratio.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>predose: ratio adjusted mean</param_type>
            <param_value>12.39</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>7.09</ci_lower_limit>
            <ci_upper_limit>21.65</ci_upper_limit>
            <estimate_desc>Estimated value = ratio (%) of adjusted geometric means comparing brain (test) vs. plama (reference) concentrations of voriconazole N-oxide.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Other estimated parameter represents the Day 3 post-dose ratio of the adjusted geometric means comparing brain vs. plasma concentrations of voriconazole N-oxide. Natural-log transformed concentrations of voriconazole were analyzed using a mixed-effects model to obtain the adjusted mean difference (Test-Reference) and 90% confidence interval for the difference which were exponentiated to provide estimates of the ratio of the adjusted geometric means and 90% CI for the ratio.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>postdose: ratio adjusted mean</param_type>
            <param_value>31.57</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>18.06</ci_lower_limit>
            <ci_upper_limit>55.18</ci_upper_limit>
            <estimate_desc>Estimated value = ratio (%) of adjusted geometric means comparing brain (test) vs. plasma (reference) concentrations of voriconazole N-oxide.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Voriconazole</title>
          <description>400 mg every 12 hours on Day 1; 200 mg every 12 hours on Day 2; 200 mg on Day 3</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of &lt; 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), &lt; 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

